Patients with operable HER2-positive breast cancer appear to benefit from the addition of pertuzumab to trastuzumab plus chemotherapy

被引：0
|
作者：
Printz, Carrie
机构：
来源：
CANCER | 2020年 / 126卷 / 09期
关键词：
D O I：
10.1002/cncr.32893
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1827 / 1827
页数：1
相关论文
共 50 条
  • [41] Clinical efficacy of combination of pertuzumab, trastuzumab, and docetaxel for treatment of patients with HER2-positive breast cancer
    Liu, Yan-cui
    Ma, Ying
    An, Ning
    Sun, Ping
    Wang, Ying
    Sun, Cheng
    MEDICINE, 2019, 98 (38)
  • [42] Pharmacokinetics of pertuzumab administered concurrently with trastuzumab in Chinese patients with HER2-positive early breast cancer
    Luo, Yang
    Li, Wei
    Jiang, Zefei
    Zhang, Qingyuan
    Wang, Liwei
    Mao, Yixiang
    Tjan-Heijnen, Vivianne C. G.
    Im, Seock-Ah
    McConnell, Robin
    Bejarano, Sara
    Fumagalli, Debora
    Bines, Jose
    Wang, Bei
    Garg, Amit
    Kirschbrown, Whitney P.
    Xu, Binghe
    ANTI-CANCER DRUGS, 2019, 30 (08) : 866 - 872
  • [43] Trastuzumab Biosimilar (HLX02), Pertuzumab Plus Chemotherapy in Patients with HER2-Positive Metastatic Breast Cancer after Progression of Trastuzumab: A Prospective, Phase II Study
    Zhang, Ruyan
    Liu, Xiaoran
    Song, Guohong
    Zhang, Yan
    Li, Huiping
    CANCER RESEARCH AND TREATMENT, 2024, 56 (03): : 795 - 801
  • [44] Complete response after pertuzumab plus trastuzumab plus docetaxel in metastatic Her2-positive breast cancer patients: review of four cases
    Lai-Tiong, F.
    EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 2018, 39 (05) : 845 - 846
  • [45] Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer
    Piccart-Gebhart, MJ
    Procter, M
    Leyland-Jones, B
    Goldhirsch, A
    Untch, M
    Smith, I
    Gianni, L
    Baselga, J
    Bell, R
    Jackisch, C
    Cameron, D
    Dowsett, M
    Barrios, CH
    Steger, G
    Huang, CS
    Andersson, M
    Inbar, M
    Lichinitser, M
    Láng, I
    Nitz, U
    Iwata, H
    Thomssen, C
    Lohrisch, C
    Suter, TM
    Ruschoff, J
    Süto, T
    Greatorex, V
    Ward, C
    Straehle, C
    McFadden, E
    Dolci, MS
    Gelber, RD
    NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (16): : 1659 - 1672
  • [46] Neoadjuvant treatment with trastuzumab and pertuzumab plus fulvestrant in older patients with HER2-positive, ER-positive early breast cancer.
    Celis, Juan Jose
    Rodriguez, Vanessa
    Rodriguez, Crismar
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (23_SUPPL) : 13 - 13
  • [47] Clinical implication of HER2 status change after neoadjuvant chemotherapy with Trastuzumab and Pertuzumab (HP) in patients with HER2-positive breast cancer
    Ferraro, Emanuela
    Safonov, Anton
    Wen, Hanna Y.
    Brogi, Edi
    Gonan, Mithat
    Barrio, Andrea V.
    Razavi, Pedram
    Chandarlapaty, Sarat
    Modi, Shanu
    Seidman, Andrew D.
    Norton, Larry
    Robson, Mark E.
    Dang, Chau T.
    CANCER RESEARCH, 2022, 82 (04)
  • [48] Trastuzumab plus pertuzumab in combination with chemotherapy in metastatic HER2-positive breast cancer: a retrospective single-armed cohort study in China
    Qian, Yu
    Peng, Ying
    Zhou, Hao
    Zhang, Lili
    Yuan, Yuan
    ANNALS OF TRANSLATIONAL MEDICINE, 2022, 10 (16)
  • [49] Interaction of TP53 mutations with trastuzumab in HER2-positive patients with operable breast cancer
    Kotoula, V.
    Zagouri, F.
    Alexopoulou, Z.
    Gogas, H.
    Lakis, S.
    Pentheroudakis, G.
    Bobos, M.
    Papadopoulou, K.
    Tsolaki, E.
    Skondra, M.
    Karavasilis, V.
    Koutras, A.
    Chrisafi, S.
    Christodoulou, C.
    Papakostas, P.
    Linardou, H.
    Markopoulos, C.
    Zografos, G.
    Samantas, E.
    Fountzilas, G.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S270 - S270
  • [50] Mode of action of pertuzumab in combination with trastuzumab plus docetaxel therapy in a HER2-positive breast cancer xenograft model
    Yamashita-Kashima, Yoriko
    Shu, Sei
    Yorozu, Keigo
    Moriya, Yoichiro
    Harada, Naoki
    ONCOLOGY LETTERS, 2017, 14 (04) : 4197 - 4205
12345